[go: up one dir, main page]

WO2002059283A3 - Nucleic acid modification enzymes - Google Patents

Nucleic acid modification enzymes Download PDF

Info

Publication number
WO2002059283A3
WO2002059283A3 PCT/US2001/046301 US0146301W WO02059283A3 WO 2002059283 A3 WO2002059283 A3 WO 2002059283A3 US 0146301 W US0146301 W US 0146301W WO 02059283 A3 WO02059283 A3 WO 02059283A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid modification
modification enzymes
namo
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/046301
Other languages
French (fr)
Other versions
WO2002059283A2 (en
Inventor
Mariah R Baughn
Henry Yue
Yan Lu
Li Ding
Y Tom Tang
Ameena R Gandhi
April J A Hafalia
Preeti G Lal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Priority to AU2002246578A priority Critical patent/AU2002246578A1/en
Priority to JP2002559570A priority patent/JP2004528825A/en
Priority to EP01994151A priority patent/EP1381678A2/en
Priority to US10/415,615 priority patent/US20040101943A1/en
Priority to CA002427647A priority patent/CA2427647A1/en
Publication of WO2002059283A2 publication Critical patent/WO2002059283A2/en
Anticipated expiration legal-status Critical
Publication of WO2002059283A3 publication Critical patent/WO2002059283A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides human nucleic acid modification enzymes (NAMO) and polynucleotides which identify and encode NAMO. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of NAMO.
PCT/US2001/046301 2000-11-02 2001-11-01 Nucleic acid modification enzymes Ceased WO2002059283A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002246578A AU2002246578A1 (en) 2000-11-02 2001-11-01 Nucleic acid modification enzymes
JP2002559570A JP2004528825A (en) 2000-11-02 2001-11-01 Nucleic acid modifying enzymes
EP01994151A EP1381678A2 (en) 2000-11-02 2001-11-01 Nucleic acid modification enzymes
US10/415,615 US20040101943A1 (en) 2001-11-01 2001-11-01 Nucleic acid modification enzymes
CA002427647A CA2427647A1 (en) 2000-11-02 2001-11-01 Nucleic acid modification enzymes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24545800P 2000-11-02 2000-11-02
US60/245,458 2000-11-02
US25510700P 2000-12-12 2000-12-12
US60/255,107 2000-12-12

Publications (2)

Publication Number Publication Date
WO2002059283A2 WO2002059283A2 (en) 2002-08-01
WO2002059283A3 true WO2002059283A3 (en) 2003-10-30

Family

ID=26937250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/046301 Ceased WO2002059283A2 (en) 2000-11-02 2001-11-01 Nucleic acid modification enzymes

Country Status (5)

Country Link
EP (1) EP1381678A2 (en)
JP (1) JP2004528825A (en)
AU (1) AU2002246578A1 (en)
CA (1) CA2427647A1 (en)
WO (1) WO2002059283A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888792A (en) * 1997-07-11 1999-03-30 Incyte Pharmaceuticals, Inc. ATP-dependent RNA helicase protein
WO2000005586A2 (en) * 1998-07-22 2000-02-03 University Of Medicine And Dentistry Of New Jersey Rna helicases modulating translation termination

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888792A (en) * 1997-07-11 1999-03-30 Incyte Pharmaceuticals, Inc. ATP-dependent RNA helicase protein
WO2000005586A2 (en) * 1998-07-22 2000-02-03 University Of Medicine And Dentistry Of New Jersey Rna helicases modulating translation termination

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] OHARA ET AL.: "Homo sapiens mRNA for KIAA1595 protein, partial cds", XP002213527, Database accession no. AB046815 *
LUEKING A ET AL: "THE PROTEIN FAMILY OF RNA HELICASES", CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, CRC PRESS, BOCA RATON, FL, US, vol. 33, no. 4, 1998, pages 259 - 296, XP000925222, ISSN: 1040-9238 *
NAGASE T ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES XVIII. THE COMPLETE SEQUENCES OF 100 NEW CDNA CLONES FROM BRAIN WHICH CODE FOR LARGE PROTEINS IN VITRO", DNA RESEARCH, UNIVERSAL ACADEMY PRESS, JP, vol. 7, no. 4, AB046815, 31 August 2000 (2000-08-31), pages 273 - 281, XP001012454, ISSN: 1340-2838 *

Also Published As

Publication number Publication date
WO2002059283A2 (en) 2002-08-01
AU2002246578A1 (en) 2002-08-06
EP1381678A2 (en) 2004-01-21
JP2004528825A (en) 2004-09-24
CA2427647A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
WO2003052075A3 (en) Enzymes
WO2001007628A3 (en) Human synthetases
WO2001051638A3 (en) Drug metabolizing enzymes
WO2001016334A3 (en) Human hydrolytic enzymes
WO2001090334A3 (en) Drug metabolizing enzymes
WO2002004612A3 (en) Drug metabolizing enzymes
WO2001046397A3 (en) Human kinases
WO2003042357A3 (en) Enzymes
WO2001096546A3 (en) Protein phosphatases
WO2003004608A3 (en) Drug metabolizing enzymes
WO2001098471A8 (en) Human phosphodiesterases
WO2002010363A3 (en) Protein phosphatases
WO2001079468A3 (en) Drug metabolizing enzymes
WO2001059127A3 (en) Drug metabolizing enzymes
WO2002024924A3 (en) Protein phosphatases
WO2001083524A3 (en) Rna metabolism proteins
WO2002026998A3 (en) Hydrolases
WO2004003162A3 (en) Enzymes
WO2001046443A3 (en) Proteases
WO2002012467A3 (en) Drug metabolizing enzymes
WO2001055358A3 (en) Phosphodiesterases
WO2003072729A3 (en) Enzymes
WO2001064907A3 (en) Lipid metabolism enzymes
WO2003083082A3 (en) Enzymes
WO2003093439A3 (en) Enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002559570

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10415615

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2427647

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001994151

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001994151

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001994151

Country of ref document: EP